Monday’s Midday Stock Update: Anthera Pharmaceuticals (ANTH), Conatus Pharmaceuticals (CNAT), ImmunoCellular Therapeutics (IMUC), Neuralstem (CUR), NovaBay Pharma (NBY)

By Carrie Williams

So far Monday, April 15, NASDAQ is down -1.04% and the S&P is down -0.53%. Here are this morning’s most active stocks: Anthera Pharmaceuticals (ANTHResearch Report), Conatus Pharmaceuticals (CNATResearch Report), ImmunoCellular Therapeutics (IMUCResearch Report), Neuralstem (CURResearch Report) and NovaBay Pharma (NBYResearch Report).

Anthera Pharmaceuticals is up 35.71% in midday trading to $0.10. Shares opened today at $0.07. The company has a 52-week low of $0.01 and a 52-week high of $0.00.

Conatus Pharmaceuticals is down -31.83% in midday trading to $0.82. Shares opened today at $1.21. The company has a 52-week low of $0.81 and a 52-week high of $0.00. On the Street’s front, the average 12-month analyst price target for the stock is $1.60, marking a 32.23% potential upside from current levels. In a report issued on March 26, Roth Capital analyst Yasmeen Rahimi downgraded CNAT to Hold, with a price target of $1.70, which represents a potential upside of 40% from where the stock is currently trading. Separately, on March 11, H.C. Wainwright’s Ed Arce maintained a Buy rating on the stock and has a price target of $8.

ImmunoCellular Therapeutics is up 18.18% in midday trading to $0.03. Shares opened today at $0.02. The company has a 52-week low of $0.01 and a 52-week high of $0.00.

See today’s analyst top recommended stocks >>

Neuralstem is down -11.6% in midday trading to $0.44. Shares opened today at $0.50. The company has a 52-week low of $0.25 and a 52-week high of $0.00.

See today’s analyst top recommended stocks >>

NovaBay Pharma is up 10.02% in midday trading to $1.07. Shares opened today at $0.97. The company has a 52-week low of $0.71 and a 52-week high of $0.00. On the Street’s front, the average 12-month analyst price target for the stock is $1.25, marking a 28.22% potential upside from current levels. In a report issued on March 29, H.C. Wainwright analyst Ram Selvaraju reiterated a Hold rating on NBY, with a price target of $1, which represents a slight upside potential from current levels.

Trending Stocks Based on Insider Activity >>